Understanding and Improving ¹⁸F-Fluciclovine PET/CT Reports: A Guide for Physicians Treating Patients with Biochemical Recurrence of Prostate Cancer

Table 1

Patient-level prostate cancer detection rate by PSA category, LOCATE study (N = 213 evaluable patients) [19].

PSA concentration category	Overall (patient-level) prostate cancer detection rate
0–0.5 ng/mL	31% (25/81)
>0.5–1.0 ng/mL	50% (13/26)
>1.0–2.0 ng/mL	66% (19/29)
>2.0–5.0 ng/mL	77% (27/35)
>5.0–10.0 ng/mL	87% (20/23)
>10.0 ng/mL	95% (18/19)

PSA, prostate-specific antigen.